C
CURIS INC
NASDAQ: CRIS (Curis, Inc.)
Last update: 13 hours ago0.714
0.05 (8.02%)
| Previous Close | 0.661 |
| Volume | 32,240,483 |
| Price / Sales | 0.160 |
| Price / Book | 0.250 |
| 52 Weeks Range |
| Operating Margin (TTM) | -426.77% |
| Diluted EPS (TTM) | -6.08 |
| Quarterly Revenue Growth (YOY) | 14.10% |
| Current Ratio (MRQ) | 1.23 |
| Operating Cash Flow (TTM) | -33.58 M |
| Levered Free Cash Flow (TTM) | -18.95 M |
| Return on Assets (TTM) | -52.08% |
| Return on Equity (TTM) | -2,951.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Curis, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 1.2 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -2.0 |
| Relative Valuation | NA |
| Financial Health | -4.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.11 |
Select this tab to load the latest available analysis.
|
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.64% |
| % Held by Institutions | 44.65% |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |